These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 23707672)
1. Prognostic factors associated with time to hCG remission in patients with low-risk postmolar gestational trophoblastic neoplasia. Maestá I; Growdon WB; Goldstein DP; Bernstein MR; Horowitz NS; Rudge MV; Berkowitz RS Gynecol Oncol; 2013 Aug; 130(2):312-6. PubMed ID: 23707672 [TBL] [Abstract][Full Text] [Related]
2. Gestational trophoblastic neoplasia after achieving a nondetectable serum human chorionic gonadotrophin level. Gueye M; Kane-Gueye SM; Ndiaye-Gueye MD; Mbaye M; Diouf AA; Niang MM; Diallo M; Moreau JC BJOG; 2014 Oct; 121(11):1415-9. PubMed ID: 24674295 [TBL] [Abstract][Full Text] [Related]
3. [Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof]. Chen YX; Shen YM; Qian JH; Xie X Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2109-12. PubMed ID: 16313819 [TBL] [Abstract][Full Text] [Related]
4. Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia? Braga A; Biscaro A; do Amaral Giordani JM; Viggiano M; Elias KM; Berkowitz RS; Seckl MJ Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():50-55. PubMed ID: 29477553 [TBL] [Abstract][Full Text] [Related]
6. Hormonal contraceptive use before hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review. Braga A; Maestá I; Short D; Savage P; Harvey R; Seckl MJ BJOG; 2016 Jul; 123(8):1330-5. PubMed ID: 26444183 [TBL] [Abstract][Full Text] [Related]
8. Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation. Braga A; Maestá I; Matos M; Elias KM; Rizzo J; Viggiano MG Gynecol Oncol; 2015 Nov; 139(2):283-7. PubMed ID: 26383828 [TBL] [Abstract][Full Text] [Related]
9. Human chorionic gonadotrophin regression rate as a predictive factor of postmolar gestational trophoblastic neoplasm in high-risk hydatidiform mole: a case-control study. Kim BW; Cho H; Kim H; Nam EJ; Kim SW; Kim S; Kim YT; Kim JH Eur J Obstet Gynecol Reprod Biol; 2012 Jan; 160(1):100-5. PubMed ID: 22055909 [TBL] [Abstract][Full Text] [Related]
10. Postmolar gestational trophoblastic neoplasia: beyond the traditional risk factors. Bakhtiyari M; Mirzamoradi M; Kimyaiee P; Aghaie A; Mansournia MA; Ashrafi-Vand S; Sarfjoo FS Fertil Steril; 2015 Sep; 104(3):649-54. PubMed ID: 26099850 [TBL] [Abstract][Full Text] [Related]
11. Postmolar choriocarcinoma: An independent risk factor for chemotherapy resistance in low-risk gestational trophoblastic neoplasia. Strohl AE; Lurain JR Gynecol Oncol; 2016 May; 141(2):276-280. PubMed ID: 26896825 [TBL] [Abstract][Full Text] [Related]
12. Risk of gestational trophoblastic neoplasia after hCG normalisation according to hydatidiform mole type. Schmitt C; Doret M; Massardier J; Hajri T; Schott AM; Raudrant D; Golfier F Gynecol Oncol; 2013 Jul; 130(1):86-9. PubMed ID: 23523617 [TBL] [Abstract][Full Text] [Related]
13. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy. Chapman-Davis E; Hoekstra AV; Rademaker AW; Schink JC; Lurain JR Gynecol Oncol; 2012 Jun; 125(3):572-5. PubMed ID: 22449733 [TBL] [Abstract][Full Text] [Related]
14. Prediction of persistent gestational trophobalstic neoplasia: the role of hCG level and ratio in 2 weeks after evacuation of complete mole. Kang WD; Choi HS; Kim SM Gynecol Oncol; 2012 Feb; 124(2):250-3. PubMed ID: 22094931 [TBL] [Abstract][Full Text] [Related]
15. Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study. Braga A; Paiva G; Ghorani E; Freitas F; Velarde LGC; Kaur B; Unsworth N; Lozano-Kuehne J; Dos Santos Esteves APV; Rezende Filho J; Amim J; Aguiar X; Sarwar N; Elias KM; Horowitz NS; Berkowitz RS; Seckl MJ Lancet Oncol; 2021 Aug; 22(8):1188-1198. PubMed ID: 34181884 [TBL] [Abstract][Full Text] [Related]
16. A Novel Prediction Model for Postmolar Gestational Trophoblastic Neoplasia and Comparison With Existing Models. Zhao P; Wang S; Zhang X; Lu W Int J Gynecol Cancer; 2017 Jun; 27(5):1028-1034. PubMed ID: 28498254 [TBL] [Abstract][Full Text] [Related]
17. Does hormonal contraception during molar pregnancy follow-up influence the risk and clinical aggressiveness of gestational trophoblastic neoplasia after controlling for risk factors? Dantas PRS; Maestá I; Filho JR; Junior JA; Elias KM; Howoritz N; Braga A; Berkowitz RS Gynecol Oncol; 2017 Nov; 147(2):364-370. PubMed ID: 28927899 [TBL] [Abstract][Full Text] [Related]
18. A 30-year experience in using oral methotrexate as initial treatment for gestational trophoblastic neoplasia regardless of risk group. Faaborg L; Niemann I; Ostenfeld EB; Hansen ES; Sunde L; Lindegaard JC Acta Oncol; 2016; 55(2):234-9. PubMed ID: 26106854 [TBL] [Abstract][Full Text] [Related]
19. [Therapeutic evaluation of cisplatin, etoposide, and bleomycin chemotherapy regimen in high-risk gestational trophoblastic neoplasia]. Song SQ; Zhang GN Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):571-6. PubMed ID: 23141175 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience. Maestá I; Nitecki R; Horowitz NS; Goldstein DP; de Freitas Segalla Moreira M; Elias KM; Berkowitz RS Gynecol Oncol; 2018 Jan; 148(1):161-167. PubMed ID: 29092742 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]